Pfizer Beats Earnings Estimates Amid Covid Product Decline

Pfizer's Q4 2026 earnings demonstrate the company's ability to outperform expectations despite headwinds from declining COVID-19 product sales. The company's success is attributed to strong demand for established drugs like Eliquis and Vyndaqel, as well as strategic investments such as the $10 billion acquisition of Metsera, an obesity biotech company. Promising mid-stage data from Metsera's obesity injection, showing potential for once-a-month dosing and significant weight loss, further bolsters Pfizer's growth prospects. Cost-cutting measures aimed at saving $7.7 billion by the end of 2027 will also contribute to the company's financial stability. The company expects a $1.5 billion year-over-year drop in sales due to certain products losing their market exclusivity and deeper discounts in its Medicaid business. These factors are important for investors to consider as they assess Pfizer's long-term potential. Pfizer's Xeljanz and Xeljanz XR were selected for Medicare drug price negotiations.

Sustained demand for older drugs and strategic investments in its pipeline, including the acquisition of Metsera.

Pfizer expects adjusted profit to be between $2.80 and $3 per share, with revenue totaling $59.5 billion to $62.5 billion.

By focusing on longer-term investments in its pipeline and cutting costs by about $7.7 billion by the end of 2027.

What are your thoughts on Pfizer's long-term growth strategy? Do you think their investments in new drugs will offset the decline in COVID-19 product sales? Share this article with others who need to stay ahead of this trend!